Controlling the confounding effect of metabolic gene expression to identify actual metabolite targets in microsatellite instability cancers.
CATCH model
Confounding effect
Metabolic gene
Metabolic targets
Metabolomic
Microsatellite instability
Journal
Human genomics
ISSN: 1479-7364
Titre abrégé: Hum Genomics
Pays: England
ID NLM: 101202210
Informations de publication
Date de publication:
06 03 2023
06 03 2023
Historique:
received:
12
12
2022
accepted:
22
02
2023
entrez:
6
3
2023
pubmed:
7
3
2023
medline:
9
3
2023
Statut:
epublish
Résumé
The metabolome is the best representation of cancer phenotypes. Gene expression can be considered a confounding covariate affecting metabolite levels. Data integration across metabolomics and genomics to establish the biological relevance of cancer metabolism is challenging. This study aimed to eliminate the confounding effect of metabolic gene expression to reflect actual metabolite levels in microsatellite instability (MSI) cancers. In this study, we propose a new strategy using covariate-adjusted tensor classification in high dimensions (CATCH) models to integrate metabolite and metabolic gene expression data to classify MSI and microsatellite stability (MSS) cancers. We used datasets from the Cancer Cell Line Encyclopedia (CCLE) phase II project and treated metabolomic data as tensor predictors and data on gene expression of metabolic enzymes as confounding covariates. The CATCH model performed well, with high accuracy (0.82), sensitivity (0.66), specificity (0.88), precision (0.65), and F1 score (0.65). Seven metabolite features adjusted for metabolic gene expression, namely, 3-phosphoglycerate, 6-phosphogluconate, cholesterol ester, lysophosphatidylethanolamine (LPE), phosphatidylcholine, reduced glutathione, and sarcosine, were found in MSI cancers. Only one metabolite, Hippurate, was present in MSS cancers. The gene expression of phosphofructokinase 1 (PFKP), which is involved in the glycolytic pathway, was related to 3-phosphoglycerate. ALDH4A1 and GPT2 were associated with sarcosine. LPE was associated with the expression of CHPT1, which is involved in lipid metabolism. The glycolysis, nucleotide, glutamate, and lipid metabolic pathways were enriched in MSI cancers. We propose an effective CATCH model for predicting MSI cancer status. By controlling the confounding effect of metabolic gene expression, we identified cancer metabolic biomarkers and therapeutic targets. In addition, we provided the possible biology and genetics of MSI cancer metabolism.
Sections du résumé
BACKGROUND
The metabolome is the best representation of cancer phenotypes. Gene expression can be considered a confounding covariate affecting metabolite levels. Data integration across metabolomics and genomics to establish the biological relevance of cancer metabolism is challenging. This study aimed to eliminate the confounding effect of metabolic gene expression to reflect actual metabolite levels in microsatellite instability (MSI) cancers.
METHODS
In this study, we propose a new strategy using covariate-adjusted tensor classification in high dimensions (CATCH) models to integrate metabolite and metabolic gene expression data to classify MSI and microsatellite stability (MSS) cancers. We used datasets from the Cancer Cell Line Encyclopedia (CCLE) phase II project and treated metabolomic data as tensor predictors and data on gene expression of metabolic enzymes as confounding covariates.
RESULTS
The CATCH model performed well, with high accuracy (0.82), sensitivity (0.66), specificity (0.88), precision (0.65), and F1 score (0.65). Seven metabolite features adjusted for metabolic gene expression, namely, 3-phosphoglycerate, 6-phosphogluconate, cholesterol ester, lysophosphatidylethanolamine (LPE), phosphatidylcholine, reduced glutathione, and sarcosine, were found in MSI cancers. Only one metabolite, Hippurate, was present in MSS cancers. The gene expression of phosphofructokinase 1 (PFKP), which is involved in the glycolytic pathway, was related to 3-phosphoglycerate. ALDH4A1 and GPT2 were associated with sarcosine. LPE was associated with the expression of CHPT1, which is involved in lipid metabolism. The glycolysis, nucleotide, glutamate, and lipid metabolic pathways were enriched in MSI cancers.
CONCLUSIONS
We propose an effective CATCH model for predicting MSI cancer status. By controlling the confounding effect of metabolic gene expression, we identified cancer metabolic biomarkers and therapeutic targets. In addition, we provided the possible biology and genetics of MSI cancer metabolism.
Identifiants
pubmed: 36879264
doi: 10.1186/s40246-023-00465-9
pii: 10.1186/s40246-023-00465-9
pmc: PMC9990231
doi:
Substances chimiques
3-phosphoglycerate
820-11-1
Sarcosine
Z711V88R5F
Glyceric Acids
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
18Informations de copyright
© 2023. The Author(s).
Références
Nat Genet. 2014 Jun;46(6):543-550
pubmed: 24816252
Cell Metab. 2022 Mar 1;34(3):355-377
pubmed: 35123658
Nat Rev Drug Discov. 2022 Feb;21(2):141-162
pubmed: 34862480
Sci Rep. 2017 Oct 20;7(1):13670
pubmed: 29057986
Cancer Med. 2018 Mar;7(3):746-756
pubmed: 29436178
Nature. 2019 Apr;568(7753):551-556
pubmed: 30971823
Nucleic Acids Res. 2022 Jan 7;50(D1):D622-D631
pubmed: 34986597
Exp Mol Pathol. 1987 Oct;47(2):154-65
pubmed: 2820786
Chem Rev. 2018 Jul 25;118(14):6893-6923
pubmed: 29939018
J Proteome Res. 2018 Apr 6;17(4):1586-1595
pubmed: 29457906
Metabolites. 2022 May 27;12(6):
pubmed: 35736421
Oxid Med Cell Longev. 2013;2013:972913
pubmed: 23766865
Trends Genet. 2013 Jan;29(1):41-50
pubmed: 23084137
Nature. 2019 May;569(7757):503-508
pubmed: 31068700
Genome Biol. 2017 May 5;18(1):83
pubmed: 28476144
Commun Biol. 2019 Nov 14;2:414
pubmed: 31754644
Cancer Res. 2020 Nov 1;80(21):4815-4827
pubmed: 32907836
Cancer Res. 1998 Nov 15;58(22):5248-57
pubmed: 9823339
Genes Dev. 2016 Nov 1;30(21):2345-2369
pubmed: 27881599
Nucleic Acids Res. 2012 Jan;40(Database issue):D400-12
pubmed: 22140110
Nature. 2012 Mar 28;483(7391):603-7
pubmed: 22460905
Nat Med. 2019 May;25(5):850-860
pubmed: 31068703
Nature. 2009 Feb 12;457(7231):910-4
pubmed: 19212411
Trends Endocrinol Metab. 2021 Jun;32(6):367-381
pubmed: 33795176
Epigenetics. 2014 Aug;9(8):1149-62
pubmed: 25089541
Mol Cell. 2018 Apr 19;70(2):197-210.e7
pubmed: 29677490
Metabolites. 2022 Apr 15;12(4):
pubmed: 35448542
Genes (Basel). 2021 Feb 09;12(2):
pubmed: 33572255
Nat Protoc. 2022 Aug;17(8):1735-1761
pubmed: 35715522
Nucleic Acids Res. 1999 Jan 1;27(1):29-34
pubmed: 9847135
Int J Gen Med. 2021 Dec 09;14:9503-9513
pubmed: 34916832
Br J Cancer. 2019 Nov;121(10):809-818
pubmed: 31607751
Bioinform Biol Insights. 2020 Jan 31;14:1177932219899051
pubmed: 32076369
J Exp Med. 2021 Jan 4;218(1):
pubmed: 33601415
Front Cell Dev Biol. 2021 Dec 24;9:793428
pubmed: 35004688
Int J Mol Sci. 2021 Jun 10;22(12):
pubmed: 34200820
Oncogenesis. 2022 Apr 14;11(1):17
pubmed: 35422484
Cancer Sci. 2012 Jun;103(6):1010-21
pubmed: 22380946
Mol Cancer Ther. 2018 Sep;17(9):1824-1832
pubmed: 30181331
Trends Biotechnol. 2005 Nov;23(11):544-6
pubmed: 16154652
Anal Chem. 2014 Jun 3;86(11):5433-40
pubmed: 24796490
Cancer Cell. 2008 Jun;13(6):472-82
pubmed: 18538731
Nat Commun. 2017 Jun 06;8:15180
pubmed: 28585546
Prostate. 2018 Feb;78(2):104-112
pubmed: 29105933
J Proteome Res. 2013 Apr 5;12(4):1527-46
pubmed: 23342949
Front Oncol. 2020 Dec 04;10:602498
pubmed: 33344254
Bioinformatics. 2021 Mar 01;:
pubmed: 33674827
Cell Metab. 2014 Dec 2;20(6):967-77
pubmed: 25456739
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308